Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIFT: Effect of Rifampicin on Descovy PK
NCT03186482Phase 1Completed
- Sponsor
- St Stephen's Clinical Research
- Start
- Jun 2017
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tenofovir alafenamide in human immunodeficiency virus infection (HIV), sponsored by St Stephen's Clinical Research. Primary endpoints: Trough Concentration at 12 weeks, Peak Plasma Concentration at 12 weeks and 3 more. Started Jun 2017; status: completed.
02
Drugs
tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03186482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03186482.